Treffer: Predicting local control of brain metastases after stereotactic radiotherapy with clinical, radiomics and deep learning features.

Title:
Predicting local control of brain metastases after stereotactic radiotherapy with clinical, radiomics and deep learning features.
Authors:
Kanakarajan H; Department of Cognitive Neuropsychology, Tilburg University, Tilburg, The Netherlands. H.Kanakarajan@tilburguniversity.edu., De Baene W; Department of Cognitive Neuropsychology, Tilburg University, Tilburg, The Netherlands. w.debaene@tilburguniversity.edu., Hanssens P; Gamma Knife Center, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.; Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands., Sitskoorn M; Department of Cognitive Neuropsychology, Tilburg University, Tilburg, The Netherlands.
Source:
Radiation oncology (London, England) [Radiat Oncol] 2024 Dec 30; Vol. 19 (1), pp. 182. Date of Electronic Publication: 2024 Dec 30.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: BioMed Central Country of Publication: England NLM ID: 101265111 Publication Model: Electronic Cited Medium: Internet ISSN: 1748-717X (Electronic) Linking ISSN: 1748717X NLM ISO Abbreviation: Radiat Oncol Subsets: MEDLINE
Imprint Name(s):
Original Publication: [London] : BioMed Central, 2006-
References:
Asian J Neurosurg. 2023 Jun 16;18(2):246-257. (PMID: 37397044)
Front Oncol. 2021 Jan 11;10:569461. (PMID: 33505904)
Nature. 2015 May 28;521(7553):436-44. (PMID: 26017442)
Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. (PMID: 27725679)
Asia Pac J Clin Oncol. 2020 Jun;16(3):165-171. (PMID: 32030901)
JAMA Oncol. 2017 Jun 01;3(6):827-831. (PMID: 27892978)
Curr Oncol. 2023 Oct 24;30(11):9382-9391. (PMID: 37999099)
Front Oncol. 2020 Oct 23;10:580919. (PMID: 33194711)
Acta Neuropathol. 2012 Feb;123(2):205-22. (PMID: 22212630)
Cancer Imaging. 2023 Oct 22;23(1):101. (PMID: 37867196)
PLoS Med. 2018 Nov 30;15(11):e1002711. (PMID: 30500819)
Eur Radiol Exp. 2018 Nov 14;2(1):36. (PMID: 30426318)
Neuro Oncol. 2020 Jun 9;22(6):797-805. (PMID: 31956919)
J Neurosurg. 2013 Nov;119(5):1139-44. (PMID: 23971958)
Med Phys. 2022 Nov;49(11):7167-7178. (PMID: 35727568)
Front Neuroinform. 2011 Aug 22;5:13. (PMID: 21897815)
JAMA. 2016 Jul 26;316(4):401-409. (PMID: 27458945)
Neurooncol Adv. 2023 Dec 10;6(1):vdad161. (PMID: 38187872)
BMC Cancer. 2024 Jan 12;24(1):69. (PMID: 38216936)
Annu Rev Biomed Eng. 2017 Jun 21;19:221-248. (PMID: 28301734)
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):812-816. (PMID: 29063850)
Cancer Treat Rev. 2003 Dec;29(6):533-40. (PMID: 14585263)
Curr Oncol Rep. 2012 Feb;14(1):48-54. (PMID: 22012633)
Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:1022-1025. (PMID: 31946067)
Evol Intell. 2022;15(1):1-22. (PMID: 33425040)
IEEE J Transl Eng Health Med. 2022 Nov 04;11:13-22. (PMID: 36478770)
Invest Radiol. 2022 Jul 1;57(7):433-443. (PMID: 35045555)
Curr Opin Oncol. 2018 Nov;30(6):390-395. (PMID: 30142093)
Insights Imaging. 2018 Aug;9(4):611-629. (PMID: 29934920)
Radiology. 2018 Dec;289(3):797-806. (PMID: 30277442)
Cancers (Basel). 2021 Aug 10;13(16):. (PMID: 34439186)
Semin Oncol. 2004 Oct;31(5):693-701. (PMID: 15497123)
J Clin Oncol. 2018 Feb 10;36(5):483-491. (PMID: 29272161)
Front Oncol. 2022 Jul 13;12:920393. (PMID: 35912214)
Contributed Indexing:
Keywords: Brain metastases; Deep learning; Local control; Radiomics; Stereotactic radiotherapy
Entry Date(s):
Date Created: 20241231 Date Completed: 20241231 Latest Revision: 20250104
Update Code:
20250114
PubMed Central ID:
PMC11684244
DOI:
10.1186/s13014-024-02573-9
PMID:
39736796
Database:
MEDLINE

Weitere Informationen

Background and Purpose: Timely identification of local failure after stereotactic radiotherapy for brain metastases allows for treatment modifications, potentially improving outcomes. While previous studies showed that adding radiomics or Deep Learning (DL) features to clinical features increased Local Control (LC) prediction accuracy, their combined potential to predict LC remains unexplored. We examined whether a model using a combination of radiomics, DL and clinical features achieves better accuracy than models using only a subset of these features.
Materials and Methods: We collected pre-treatment brain MRIs (TR/TE: 25/1.86 ms, FOV: 210 × 210 × 150, flip angle: 30°, transverse slice orientation, voxel size: 0.82 × 0.82 × 1.5 mm) and clinical data for 129 patients at the Gamma Knife Center of the Elisabeth-TweeSteden Hospital. Radiomics features were extracted using the Python radiomics feature extractor and DL features were obtained using a 3D ResNet model. A Random Forest machine learning algorithm was employed to train four models using: (1) clinical features only; (2) clinical and radiomics features; (3) clinical and DL features; and (4) clinical, radiomics, and DL features. The average accuracy and other metrics were derived using K-fold cross validation.
Results: The prediction model utilizing only clinical variables provided an Area Under the receiver operating characteristic Curve (AUC) of 0.85 and an accuracy of 75.0%. Adding radiomics features increased the AUC to 0.86 and accuracy to 79.33%, while adding DL features resulted in an AUC of 0.82 and accuracy of 78.0%. The best performance came from combining clinical, radiomics, and DL features, achieving an AUC of 0.88 and accuracy of 81.66%. This model's prediction improvement was statistically significant compared to models trained with clinical features alone or with the combination of clinical and DL features. However, the improvement was not statistically significant when compared to the model trained with clinical and radiomics features.
Conclusion: Integrating radiomics and DL features with clinical characteristics improves prediction of local control after stereotactic radiotherapy for brain metastases. Models incorporating radiomics features consistently outperformed those utilizing clinical features alone or clinical and DL features. The increased prediction accuracy of our integrated model demonstrates the potential for early outcome prediction, enabling timely treatment modifications to improve patient management.
(© 2024. The Author(s).)

Declarations. Ethics approval and consent to participate: This study is part of the AI in Medical Imaging for novel Cancer User Support (AMICUS) project at Tilburg University. This project is approved by the Ethics Review Board at the Tilburg University. Consent to participate: The data did not contain any identifiable personal information, therefore the need for consent to participate was waived by the Institutional Review Board Elisabeth-TweeSteden Hospital (ETZ), Tilburg, The Netherlands (Study number: L1267.2021-AMICUS). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.